retatrutide clinical trials philippines GLP-1 Agonists Market Report 2025-2033,
Description
Stevanato estimates that oral GLP-1s will capture a 30% market share by 2030, though precise forecasting remains elusive
While the risk of hypoglycemia is low with GLP-1 receptor agonists alone, this risk increases when combined with insulin or sulfonylureas
Semaglutide is a compounded medication used in weight loss treatments
The extent to which GLP-1R activation of BAT contributes to weight loss in humans is still a matter of debate
however, it is still premature to advise patients to begin or cease taking these medications should they be concerned about the relationship to AMD
